(NASDAQ:VRTX) has recently achieved a significant milestone with the FDA's approval of JOURNAVX(suzetrigine), a novel ...

Non-opioid pain therapies are entering an unprecedented era, marked by the landmark FDA approval of Vertex’s Journavx and a ...

Despite not differentiating itself from placebo, the Texas-based company said it plans to push pilavapadin into Phase III ...

Vertex just won approval for a drug to treat ... medicines that sometimes aren't efficacious enough or may lead to side effects -- such as liver toxicity in the case of acetaminophen -- and ...

Detailed price information for Vertex Inc Cl A (VERX-Q) from The Globe and Mail including charting and trades.

Vertex Pharmaceuticals (NASDAQ ... medicines that sometimes aren't efficacious enough or may lead to side effects -- such as liver toxicity in the case of acetaminophen -- and opioid drugs ...

Vertex's Journavx got FDA approval for acute ... due to adverse events and manageable side effects (e.g., pruritus, muscle spasms, and rash). Journavx is dosed twice-daily (50 mg with or without ...

Pediatric AGA prevalence may be higher than previously described and over 8% of patients with pediatric AGA had disease onset prior to puberty.

The US FDA has approved Journavx, a new pain reliever without the risks for addiction or overdose linked to drugs like Vicodin and OxyContin.

“Vertex’s 2024 financial results demonstrated ... our expectations regarding the effects of the Capped Call Transactions and regarding actions of the Option Counterparties and/or their ...

Risinger also notes that the drug’s side effects are consistent with clinical trial data, and he looks forward to further insights from Vertex’s upcoming earnings call, reinforcing his ...